menu ☰
menu ˟

Minister asked to intervene with NCPE

19 Dec 2016

The Alpha One Foundation has called on the Minister for Health to intervene following a decision by the National Centre for Pharmacoeconomics (NCPE) not to approve funding of Respreeza (zemaira) for genetic emphysema, known as alpha-1 antitrypsin deficiency (AATD) or Alpha-1.

Respreeza is the only treatment shown to slow the progression of the disease; however, approval for funding reimbursement has been declined by the NCPE at the €84,364.80 cost (excluding VAT) submitted by its maker, CSL Behring.

The Foundation is also calling on the company to reduce the high price of the drug and lift its January deadline to stop providing the therapy to 21 people who have been receiving the drug on a compassionate basis since a clinical trial of the therapy got under way in 2006.

The decision also means that a further estimated 40 patients who it is thought would be eligible for the therapy continue to face an excessive wait.

The post Minister asked to intervene with NCPE appeared first on Irish Medical Times.

Click here to view the full article which appeared in Irish Medical Times